Loading
Latest filing published 29 Apr 2026 for Sino Biopharmaceutical Ltd., €1.2M.
Based on 2 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Tse Ping, listed as chief executive, appears in our data through filings on Sino Biopharmaceutical Ltd. shares, published by HKEX. We count 9 filings; the first trade dates from 19 June 2018 and the latest from 29 April 2026.
On the open market, the record shows 6 purchases worth €12.0M and 3 sales worth €618.5M. No amount is published for 3 filings, which the totals therefore leave out. Unlike grants, an open-market purchase is paid for by the insider, at the market price. 2026 to date brings 2 purchases and no sales.
A typical purchase (the median) is worth €2.8M.
The latest filing, published on 29 April 2026, reports an open-market purchase of €1.2M in Sino Biopharmaceutical Ltd. Half of the filings or more reach the HKEX feed on the day of the trade. This delay matters because a trade only becomes useful information once it is public. Source: insider filings from HKEX. Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
9 of 9 declarations